{
"id":"9292a6c479b86e0d20481907a8d2a61dedb3b67de643cf57e190da2c8a41f6bb",
"pubkey":"eb38345e0a3a1603793c57178730b781d37e9eb87746a705cb098a14d3a0b122",
"created_at":1791868025,
"kind":1,
"tags": [
[
"e",
"b18abb745010e9e2966c3e969740e10562514fcb7210f416a1d9e8c1874ac3b1",
"wss://relay.damus.io",
"root",
"eb38345e0a3a1603793c57178730b781d37e9eb87746a705cb098a14d3a0b122"
],
[
"client",
"Damus"
]
],
"content":"I assume the reporting wouldn't be to the drug group or to the hybrid product group? Please clarify per reporting organization.",
"sig":"091c6d0c336354ead227e94b4235c7e44b68a82a991489d1ba2afc77aa2283d111e374d8e02af3fa7a717b5785d7809f61bd999d1aa5262a0de08385721721de"
}